Slide 1: SRI Investor Presentation
SRI Investor Presentation September 2025
Slide 2: Agenda
Agenda Overview | Mission Green sustainability Social responsibility Governance 2
Slide 3: Sartorius at a glance
Sartorius at a glance ~€3.4bn Two divisions focused on attractive biopharma and life science Sales revenue markets ~14% Sales CAGR 2014-2024 28.0% 80% Sales 2024 20% Bioprocess Solutions Lab Products & Services EBITDA margin1 Division ~€3.4bn Division ~75% Recurring revenues ~13,500 ~85% Employees 1
Slide 4: Simplifying progress: Enabling the discovery and production of biopharmaceuticals
Simplifying progress: Enabling the discovery and production of biopharmaceuticals Bioprocess Solutions Division Molecule Cell line and Upstream & development process development downstream production Quality | Testing | Validation Lab Products & Services Division 4
Slide 5: Long-term value creation by focusing on four material topics
Long-term value creation by focusing on four material topics 1 Economic 1 ▪ Advance innovation, contribute to medical progress performance ▪ Protect the environment by reducing emissions, waste and water use 2 ▪ Assuming responsibility for our products throughout their life cycles 4 Long-term 2 Gove
Slide 6: Partner of life science research and the biopharmaceutical industry
Partner of life science research and the biopharmaceutical industry Our mission We empower scientists and engineers to simplify and accelerate progress in Good health and well-being at life science and bioprocessing, enabling the focus of Sartorius‘ the development of new and better therapies busine
Slide 7: Health is one of the most relevant global topics
Health is one of the most relevant global topics Growing and aging Development and manufacturing of drugs population are time-consuming and costly2 World population over 65 years1 Research > Commercial production ~ 1.6bn ~0.8bn 2022 2050 >€2bn 1 out of 10,000 > of 10 years 1 United Nations: World Po
Slide 8: The result: Biotech medications are extremely expensive
The result: Biotech medications are extremely expensive Rheumatism Blood cancer Hemophilia Monoclonal antibody therapy CAR-T cell therapy Gene therapy ~€12,000 ~€280,000 ~€3.5 mn Annual cost of treatment in Germany Cost per treatment in Europe Cost per treatment in the USA 8
Slide 9: Three drivers for innovation: The key to achieve ESG targets
Three drivers for innovation: The key to achieve ESG targets Product Acquisitions development of complementary and in areas of own core competencies differentiating technologies Downstream Cell and gene Bioanalytics processing therapies 3D cell printing Advanced materials Cooperations technology wit
Slide 10: Sartorius' technologies enable researchers to achieve results faster, ...
Sartorius’ technologies enable researchers to achieve results faster, ... Example: digitalization and automation of laboratory processes ▪ More experiments with lower error rate ▪ Data and analysis for better decisions ▪ Shortening time-to-clinic Incucyte® SX5 iQue®3 Octet® Saves more than 5 weeks i
Slide 11: ... to increase yield and efficiency in biopharma production ...
… to increase yield and efficiency in biopharma production … Example: innovative bioprocess technologies Downstream processing time reduced by 60% Significantly higher yields of viral vectors required for gene therapies CIMmultus® 20x Higher productivity compared to classical column chromatography S
Slide 12: ... and to improve the customers' eco-footprint through single-use technologies
... and to improve the customers' eco-footprint through single-use technologies Water consumption1 Energy consumption1 ~ -30% ~ -30% Celsius® FFT Freeze Maxicaps® Sartopore® Flexsafe® Linkit® AX & Thaw Solutions Sterile filter Platinum 1 Based on data from Flanagan et al (2011). LCA of a mAb process
Slide 13: A strong lever of impact on green aspects: Our customers' operations
A strong lever of impact on green aspects: Our customers‘ operations Global GHG emissions in CO2 Of these related to the Attributable emissions of equivalents in 20211 healthcare sector2 Sartorius3 make up >50 billion tons ~4-5% ~0.025% 1 UN Environment Programme „Emissions Gap Report 2022“, prelimi
Slide 14: Process intensification leads to higher efficiency and less eco impact
Process intensification leads to higher efficiency and less eco impact Process Mass Intensification1 -50% Total raw materials, consumables and water (kg) Resolute® BioSMB Biostat® STR Bioreactors Ambr® 250HT Perfusion PMI = Product (kg) 1 Data from in-house case study: 300 kg/year and 1,500 kg/year
Slide 15: Data analytics solutions support customers in further CO2 reduction
Data analytics solutions support customers in further CO2 reduction Success Story Implementation of Umetrics® Suite data analytics tools at Michigan University helps increase process efficiency and reduces carbon footprint significantly Phase 1 | Phase 2 | prevented aims to prevent 780 10,000 tons C
Slide 16: Agenda
Agenda Overview | Mission Green sustainability Social responsibility Governance 16
Slide 17: CO2 reduction levers across the value chain
CO2 reduction levers across the value chain Upstream Production Downstream (Scope 3) Scope 1&2 (Scope 3) Other (capital goods, Purchased Upstream incl. Business Manufacturing Down-stream Product use & employee commuting, goods & services int. transportation travel & warehousing transportation end of
Slide 18: Taking responsibility along the entire value chain
Taking responsibility along the entire value chain Direct emissions Scope 1 from sources for which we are responsible, such as our manufacturing processes or company vehicles. ~7% Indirect emissions of total GHG emissions Scope 2 from purchased electricity, steam, heating and cooling at our 60+ site
Slide 19: Ambitious sustainability agenda in implementation
Ambitious sustainability agenda in implementation 2030 mid-term ambitions 2045 long-term ambition ~10% Zero 100% Net-zero av. reduction of CO2eq emission intensity p.a. (Scopes 1-3) avoidable1 emissions in Scopes 1 and 2 electricity from renewable sources emissions Decarbonization of the entire supp
Slide 20: Expanding renewable energy capacity at our sites worldwide
Expanding renewable energy capacity at our sites worldwide* Helsinki, FI Ann Arbor, US Aubagne, FR ▪ Use of wind power Renewable power supply ▪ 200 kWh solar panels ▪ solar, hydropower and wind ▪ Capacity for up to 75 electric energy vehicle charging stations Bejing, CN ▪ New plant built to LEED Gol
Slide 21: Current projects regarding the single-use technology life cycle
Current projects regarding the single-use technology life cycle Feedstock | Beginning of life Production Product usage Product end of life Resins Product Fossil Naphtha Crackers Packaging Resins Alternative Feedstock 1 Scrap PMI 4 Recycling Options 5 Reduction 3 Recycling Less Material 2 Program 21
Slide 22: Flexsafe - first film designed for recycling
Flexsafe®- first film designed for recycling A milestone on the way to circularity ▪ From 20ml to 2,000l, Flexsafe® is the first film in the industry designed for recycling in a standard polyethylene waste stream ▪ Used in bioprocessing for non-hazardous applications, it can technically be recycled
Slide 23: Water and wastewater: Improve water efficiency in own operations
Water and wastewater: Improve water efficiency in own operations The ambitions ▪ Reduce use of drinking water, increase use of rainwater ▪ Decrease wastewater, increase water recycling Göttingen, GER ▪ Optimization of production cycles with solvents ▪ Distillation plant for almost closed solvent cyc
Slide 24: Additionally, single-use solutions reduce water usage during life cycle
Additionally, single-use solutions reduce water usage during life cycle The two most water-intense steps at our customers’ Biostat® STR bioreactors ▪ Stainless-steel process: ~80% of water used for cleaning ▪ Single-use process: ~62% of water used in chromatography Eliminate the use of water and che
Slide 25: Agenda
Agenda Overview | Mission Green sustainability Social responsibility Governance 25
Slide 26: Strong increase in personnel over 5 years
Strong increase in personnel over 5 years Focus on efficiency after strong team growth Dynamic internal job market ~2,900 new jobs 50% 15,942 14,614 13,832 13,528 69% 10,637 of employees with the company < 5years of management 2020 2021 2022 2023 2024 positions filled internally As of December 31, 2
Slide 27: Diverse and balanced employee structure
Diverse and balanced employee structure International workforce Balanced age structure Current gender structure ≤29 years 14% Share of women in 112 Nationalities 39% the entire workforce 30-39 years 37% Share of women in 69% Non-German managers 40-49 years 26% 25% Executive board ≥50 years 23% Share
Slide 28: High employee satisfaction reflected internally and externally
High employee satisfaction reflected internally and externally 85% 73% 81% say they contribute to are proud to work agree that Sartorius respects the company's mission for Sartorius and strengthens diversity 3.6 4.0 Intern. competitors ∅ 3.5 DAX40 ∅ 3.8 As of February 2025 28
Slide 29: Promoting science, education and innovation – also beyond our walls
Promoting science, education and innovation – also beyond our walls 1 2 Cell Culture Facility at Penn State 1 Supporting groundbreaking research with $1.5 million and simplifying tools 2 Life Science Factory Promoting startups and attract entrepreneurs in life sciences University Cooperations & Scho
Slide 30: Engaged in humanitarian aid and disaster relief as a global citizen
Engaged in humanitarian aid and disaster relief as a global citizen action medeor provides medical care to humanitarian organizations and health centers all over the world. Our latest commitments include: ▪ Support for earthquake victims of in Türkiye and Syria ▪ Humanitarian aid for the people of U
Slide 31: Agenda
Agenda Overview | Mission Green sustainability Social responsibility Governance 31
Slide 32: Sartorius actively manages its sustainability impacts, risks and opportunities
Sartorius actively manages its sustainability impacts, risks and opportunities at its own operations Existing and upcoming Annual management process EU regulation Corporate Sustainability 1 2 3 Due Diligence Directive (CSDDD) Identify Assess Define measures / relevant topics material IRO action plan
Slide 33: Sustainability ratings and partnerships for Sartorius AG
Sustainability ratings and partnerships for Sartorius AG Apply responsible investment strategies throughout the investment cycle. ESG ratings 2023 C AA Low risk Prime Reporting Partnerships 33
Slide 34: Sustainability ratings and partnerships for Sartorius Stedim Biotech
Sustainability ratings and partnerships for Sartorius Stedim Biotech Apply responsible investment strategies throughout the investment cycle. ESG ratings BBB Low risk Prime Reporting Partnerships 34
Slide 35: Sartorius legal structure
Sartorius legal structure Sartorius Group legal setup Sartorius AG (~69.0m shares) Ordinary shares (~34.2m shares) Preference shares (~34.8m shares) Stock market listed in Germany1 ~55% Administered by executor ~72% Free float ~38% Bio-Rad Laboratories ~28% Bio-Rad Laboratories ~7% Free float ~71.5%
Slide 36: Executive Board of Sartorius AG as of July 1, 2025
Executive Board of Sartorius AG as of July 1, 2025 Michael Grosse, CEO René Fáber Florian Funck, CFO Alexandra Gatzemeyer Joined Sartorius in 2025 Joined Sartorius in 2002 Joined Sartorius in 2024 Joined Sartorius in 2005 Member of the Board since Member of the Board since 2019 Member of the Board s
Slide 37: Two-tier Board system of Sartorius AG – Supervisory Board and its committees
Two-tier Board system of Sartorius AG – Supervisory Board and its committees ▪ Twelve members, half of the members are shareholders` representatives and half are employees’ representatives Executive Task Committee Nomination Committee Dr. Lothar Kappich (Chairman) Dr. Lothar Kappich (Chairman) Annet
Slide 38: One-tier Board of Sartorius Stedim Biotech S.A. subgroup
One-tier Board of Sartorius Stedim Biotech S.A. subgroup Dr. Dr. René Romaine Pascale Susan Cecile Anne-Marie Lothar Christopher Share of Michael Fáber Fernandes Boissel Dexter Dussart Graffin Kappich Nowers independent Grosse CEO Employee members Chairman Representative Audit & Sustainability 100%
Slide 39: ESG aspects included in Sartorius AG executive remuneration
ESG aspects included in Sartorius AG executive remuneration Remuneration Maximum bonus Maximum Structure of the remuneration components Further benefits components (in % of the target amount) remuneration Fixed remuneration Basic remuneration + Fringe benefits 100% Compensation for post- Fixed contr
Slide 40: Corporate responsibility & further financial information
Corporate responsibility & further financial information To Sartorius, sustainability means operating Please click below for further financial information: responsibly over the long term – with respect to business partners, employees and society as well as to natural resources. Learn more about our
Slide 41: Contacts and Financial calendar
Contacts and Financial calendar ▪ October 16, 2025 Publication 9M | 2025 Results Petra Müller Head of Investor Relations +49.551.308.6035 petra.mueller2@sartorius.com Mirko Koch Manager Investor Relations +49.551.308.2402 mirko.koch@sartorius.com Sartorius Corporate Administration GmbH Otto-Brenner-
Slide 42: Disclaimer
Disclaimer This presentation contains statements concerning the future performance of the Sartorius Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize.
Slide 43: Simplifying Progress
Simplifying Progress Scan or click here to visit our IR website. Scan or click here to visit our IR website.